NUVECTIS PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.5 USD | -0.61% |
|
-1.22% | -22.06% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 109.8 | 144.5 | 119.3 | - | - |
| Enterprise Value (EV) 1 | 109.8 | 144.5 | 119.3 | 119.3 | 119.3 |
| P/E ratio | -4.97 x | -5.83 x | -5.04 x | -4.61 x | -4.16 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 60.5 x |
| EV / Revenue | - | - | - | - | 60.5 x |
| EV / EBITDA | -5.71 x | -6.31 x | -4.77 x | -4.06 x | -3.46 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 14,642 | 17,327 | 18,356 | - | - |
| Reference price 2 | 7.500 | 8.340 | 6.500 | 6.500 | 6.500 |
| Announcement Date | 08/03/23 | 05/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 1.971 |
| EBITDA 1 | -12.89 | -19.23 | -22.9 | -25 | -29.4 | -34.5 |
| EBIT 1 | -12.89 | -19.23 | -22.9 | -24.68 | -29.49 | -34 |
| Operating Margin | - | - | - | - | - | -1,725.42% |
| Earnings before Tax (EBT) 1 | -12.89 | -19.08 | -22.26 | -24.04 | -29.1 | -33.52 |
| Net income 1 | -12.89 | -19.08 | -22.26 | -24.04 | -29.1 | -33.52 |
| Net margin | - | - | - | - | - | -1,700.81% |
| EPS 2 | -3.020 | -1.510 | -1.430 | -1.290 | -1.410 | -1.563 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 08/03/23 | 05/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -2.265 | -2.945 | -3.573 | -5.938 | -6.778 | - | -5.772 | -6.158 | -6.866 | -4.396 | -5.4 | -7.2 | -8 |
| EBIT 1 | - | -2.945 | -3.573 | -5.938 | -6.778 | -4.101 | -5.772 | -6.158 | -6.866 | -4.396 | -6.005 | -6.216 | -6.492 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.261 | -2.943 | -3.569 | -5.877 | -6.696 | -4.049 | -5.708 | -5.881 | -6.622 | -4.171 | -5.694 | -6.426 | -6.825 |
| Net income 1 | -2.261 | -2.943 | -3.569 | -5.877 | -6.696 | -4.049 | -5.708 | -5.881 | -6.622 | -4.171 | -5.694 | -6.426 | -6.825 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4800 | -0.3200 | -0.2800 | -0.4200 | -0.4800 | -0.2700 | -0.3800 | -0.3700 | -0.4100 | -0.2500 | -0.3067 | -0.3367 | -0.3433 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 12/05/22 | 10/08/22 | 08/11/22 | 08/03/23 | 10/05/23 | 09/08/23 | 08/11/23 | 05/03/24 | 07/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 08/03/23 | 05/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.5
USD
Average target price
22
USD
Spread / Average Target
+238.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.06% | 120M | |
| +16.73% | 121B | |
| +13.04% | 107B | |
| -5.80% | 24.82B | |
| +1.69% | 22.48B | |
| -10.09% | 18.32B | |
| -40.52% | 16.33B | |
| -14.00% | 15.31B | |
| +1.18% | 14.08B | |
| +24.18% | 11.74B |
- Stock Market
- Equities
- NVCT Stock
- Financials Nuvectis Pharma, Inc.
